Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: mmnydoc who wrote (1449)	1/13/1999 11:56:00 PM
From: marc ultra	Read Replies (1) \| Respond to of 2135

Suggest you follow Yahoo for ENMD if you can stand the constant spam The reason for last weeks gain: he following is an excerpt from a Dow Jones News wire dated the 8th Vanguard Capital analyst Stephen G. Brozak said the data in Cancer Research "solidly reinforces the potential for endostatin." Brozak expects EntreMed to reap the benefits of its discoveries soon. "This article gives validation to endostatin in halting tumor cell reproduction," he said. In Cancer Research, which the American Association for Cancer Research publishes, the endostatin data comes from researchers from Beth Israel Deaconess Medical Center and Harvard Medical School. The report from the researchers, who looked at mice with cancerous kidney cells, said, "A 2.5-fold decrease in tumor volume was observed on the fifth day after treatment between control and treated groups. The growth of the tumor was suppressed in all of the treatment groups: a slower rate was seen compared with the control group. "Endostatin administration didn't inhibit tumor growth completely: the growth of the tumors slowed, with a marginal increase in volume during the treatment period." Van Kasper & Co. analyst Alan Auerbach said the published data is very important to EntreMed. "There have been definite concerns because of the inability of certain researchers to duplicate EntreMed's data," he said. "This report in Cancer Research is probably the first of many." Posted: Jan 9 1999 7:20AM EST